Divis Laboratories Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/tn4gum3g72kxibq9nt7hbyaa.pdf

Key Takeaways


Custom Synthesis Pipeline & Commercialization

Dr. Kiran S. Divi: "By the end -- by 2027, we should start seeing commercialization post our customers, they start approving the product."

Peptide Business Build-Out

Dr. Kiran S. Divi: "I'm not at the liberty to speak about capacity created, but the validations are going on as we speak right now because pilot work is done, now it's moving towards validations."

Generics & Operating Environment


Margins & Financials

Nilima Prasad Divi: "We are not hedging. We are evaluating at this point based on the overall scenario in the market."

Technology & Process Innovation

Dr. Kiran S. Divi: "It's not complicated, okay, we will manufacture it based on the technology he has provided because they're only manufacturing fragments for innovators. They are not in the generic business."

Guidance & Commitments

CommitmentSpecificsTimeline
Dedicated capex commercializationAll 3 molecules declared to SEBI begin commercial volumes, subject to regulatory approvalsQ3/Q4 calendar year 2027
CS project commercial volumesMultiple projects moving closer to commercial volumes; validations completed or ongoingNext 1 year (broadly H2 FY27, product-dependent)
Double-digit growth trajectoryNo disruption foreseen; equilibrium maintained as products move through lifecycleOngoing
Gross asset turnover ratioReturn to historical high of 1.5 to 1.8Next 4-5 years
Raw material environmentExpected to remain broadly stable in pricing and availabilityNext 6 months
Nutraceuticals momentumHealthy performance expected to carry forwardOngoing

Key Metrics

MetricQ3 FY26
Consolidated total income₹2,692 cr, compared to ₹2,401 cr in Q3 FY25
Profit before exceptional item and tax₹854 cr, compared to ₹726 cr in Q3 FY25
Exceptional item (labour codes impact)₹74 cr, one-time incremental employee benefit obligation
Profit before tax (after exceptional item)₹780 cr
Profit after tax₹583 cr, broadly in line with ₹589 cr in Q3 FY25
Material consumption36.3% of sales revenue, vs 39.8% in Q3 FY25
Product mix (Generics / CS)43% / 57%
Export share~89% of total sales revenue; Europe and US 73% of export sales
Nutraceutical segment revenue₹214 cr
Foreign exchange gain₹19 cr, included in other income
9-month constant currency growth8.6%
Capacity utilization70% to 80%, varying by month and shipment timing
Assets capitalized (quarter)₹313 cr
Capital work in progress₹2,394 cr as of Dec 31, 2025
Cash and cash equivalents₹3,686 cr as of Dec 31, 2025
Domestic supplier base78% of procurement quantity